Cart
sales@molnova.com
LMI-070
CAS No. 1562338-42-4
LMI-070( NVS-SM1 | Branaplam )
Catalog No. M12226 CAS No. 1562338-42-4
LMI070 (NVS-SM1, Branaplam ) is a potent SMN2 splice modulator (EC50=20 nM) that potential treatment of spinal muscular atrophy (SMA).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 52 | In Stock |
|
| 5MG | 88 | In Stock |
|
| 10MG | 138 | In Stock |
|
| 25MG | 221 | In Stock |
|
| 50MG | 331 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLMI-070
-
NoteResearch use only, not for human use.
-
Brief DescriptionLMI070 (NVS-SM1, Branaplam ) is a potent SMN2 splice modulator (EC50=20 nM) that potential treatment of spinal muscular atrophy (SMA).
-
DescriptionLMI070 (NVS-SM1, Branaplam ) is a potent SMN2 splice modulator (EC50=20 nM) that potential treatment of spinal muscular atrophy (SMA).Spinal Muscular Atrophy (SMA),Phase 2 Clinical.
-
In Vitro——
-
In VivoAnimal Model:C/+ SMA mouse model Dosage:3, 10, 30 mg/kg Administration:Oral Result:Produced dose-dependent elevations of SMN2-FL transcript and SMN protein in brain and spinal cord.Animal Model:Male Sprague-Dawley rat Dosage:1 mg/kg (IV);3 mg/kg (PO) (Pharmacokinetic Analysis) Administration:IV or PO Result:Had a CL of 25 mL/min/kg and an AUC of 3.03 μM?h.
-
SynonymsNVS-SM1 | Branaplam
-
PathwayOthers
-
TargetSMN2
-
RecptorOthers
-
Research AreaNeurological Disease
-
IndicationSpinal Muscular Atrophy(SMA)
Chemical Information
-
CAS Number1562338-42-4
-
Formula Weight393.4821
-
Molecular FormulaC22H27N5O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 6.12 mg/mL
-
SMILESCC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=C3)C4=CNN=C4)O)C
-
Chemical NamePhenol, 5-(1H-pyrazol-4-yl)-2-[6-[(2,2,6,6-tetramethyl-4-piperidinyl)oxy]-3-pyridazinyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Calder AN, et al. J Med Chem. 2016 Nov 23;59(22):10067-10083.
2. Palacino J, et al. Nat Chem Biol. 2015 Jul;11(7):511-7.
molnova catalog
related products
-
Risdiplam
Risdiplam (RG7916, RG-7916, RO7034067) is a highly potent, selective, orally active?SMN2 splicing modifier for treatment of?spinal muscular atrophy (SMA).
-
D-156844
D156844 is a potent SMN2 inducer and DcpS inhibitor; highly potent at activating SMN2 promoter activity with EC50 of 4 nM.
-
LMI-070
LMI070 (NVS-SM1, Branaplam ) is a potent SMN2 splice modulator (EC50=20 nM) that potential treatment of spinal muscular atrophy (SMA).
